PCSK9 is a novel therapeutic target for familial hypercholesterolemia designed for lowering cardiovascular risk (PCSK9 is observed in carotid atherosclerotic lesions) through monoclonal antibodies and small interfering RNA [19,20]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.